

Choroidal Neovascularization

[View the current Choroidal Neovascularization InDepth page on BioPortfolio.com \(PDF\)](http://www.bioportfolio.com/indepth/Choroidal_Neovascularization.html)
(http://www.bioportfolio.com/indepth/Choroidal_Neovascularization.html) - Regularly Updated.

Recent Publications on Choroidal Neovascularization:



- [A new macular dystrophy with anomalous vascular development, pigment spots, cystic spaces, and neovascularization.](#)
OBJECTIVE: To clinically phenotype an inherited macular dystrophy with... 18th November, 2009
Department of Ophthalmology and Visual Sciences, University of Iowa Roy J.- Arch Ophthalmol. 2009 Nov;127(11):1449-57. ([DOI Direct Link](#))
- [\[Central serous choroidoretinopathy--the characteristics of the clinical picture and the evaluation of the influence of general conditions at the prognosis and the course of the disease. Metaanalysis\]](#)
Central serous choroidoretinopathy (CSCR)--recurrent disorder... 18th November, 2009
Katedra i Klinika Okulistyki Uniwersytetu Medycznego im. Karola- Klin Oczna. 2009;111(7-9):258-62.
- [Low-fluence-rate photodynamic therapy to treat subfoveal choroidal neovascularization in pathological myopia. A study of efficacy and safety.](#)
BACKGROUND: To evaluate the efficacy and safety of low-fluence-rate... 17th November, 2009
Department of Ophthalmology and ENT, University of Bari, Piazza Giulio- Graefes Arch Clin Exp Ophthalmol. 2009 Nov 15. ([DOI Direct Link](#))
- [Atrial Natriuretic Peptide Reduces Vascular Leakage and Choroidal Neovascularization.](#)
Atrial natriuretic peptide (ANP) is a hormone with diuretic, natriuretic,... 17th November, 2009
From the Angiogenesis Laboratory,* Massachusetts Eye & Ear Infirmary, and- Am J Pathol. 2009 Nov 12. ([DOI Direct Link](#))
- [Bevacizumab local complications.](#)
Choroidal neovascularization (CNV) is the major cause of severe vision... 13th November, 2009
- Ophthalmology. 2009 Nov;116(11):2264.e1-3. ([DOI Direct Link](#))
- [Angiographic changes after bevacizumab.](#)
Choroidal neovascularization (CNV) is the major cause of severe vision... 13th November, 2009
- Ophthalmology. 2009 Nov;116(11):2263.e1. ([DOI Direct Link](#))
- [\[Ranibizumab as treatment for myopic choroidal neovascularization.\]](#)
OBJECTIVE: To evaluate the efficacy of intravitreal Ranibizumab as... 11th November, 2009
Servicio de Oftalmologia, Hospital Universitario Miguel Servet, Zaragoza,- Arch Soc Esp Oftalmol. 2009 Oct;84(10):507-14.
- [Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.](#)
PURPOSE: The purpose of this study was to assess the efficacy of... 10th November, 2009
Department of Ophthalmology, Indiana University School of Medicine,- Retina. 2009 Nov-Dec;29(10):1418-23. ([DOI Direct Link](#))

- [Standard-Fluence versus Low-Fluence Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Nonrandomized Clinical Trial.](#)
*PURPOSE: To evaluate the efficacy of low-fluence compared with...*10th November, 2009
Department of Ophthalmology, University of Catania, Catania, Italy.- Am J Ophthalmol. 2009 Nov 5. ([DOI Direct Link](#))
- [Nanoparticle-integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats.](#)
*Choroidal neovascularization (CNV) is the major cause of severe vision...*10th November, 2009
Chemical and Biomolecular Engineering, Sogang University, #1 Shinsu-dong- J Control Release. 2009 Nov 4. ([DOI Direct Link](#))
- [Reticular macular disease.](#)
*PURPOSE: To present a unified description of reticular macular disease...*6th November, 2009
Department of Ophthalmology, Columbia University, New York, NY 10032, USA.- Am J Ophthalmol. 2009 Nov;148(5):733-743.e2. ([DOI Direct Link](#))
- [Pars plana vitrectomy for vitreoretinal complications of ocular toxoplasmosis.](#)
*Purpose. Ocular toxoplasmosis is associated with vitreoretinal...*3rd November, 2009
Department of Ophthalmology, Hospital Clinic de Barcelona, Universidad de- Eur J Ophthalmol. 2009 Nov-Dec;19(6):1040-4.
- [Effects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degeneration.](#)
*Abstract. Purpose: This open-label, prospective, small-scale study...*3rd November, 2009
Department of Ophthalmology, Inselspital, University Bern, Switzerland.- Acta Ophthalmol. 2009 Oct 30. ([DOI Direct Link](#))
- [Age-related macular degeneration in a screened South Korean population: prevalence, risk factors, and subtypes.](#)
*PURPOSE: To identify the prevalence, risk factors, and subtypes of...*31st October, 2009
Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan- Ophthalmic Epidemiol. 2009 Sep-Oct;16(5):304-10.
- [Intravitreal bevacizumab for choroidal neovascularization secondary to inflammation.](#)
*PURPOSE: To identify the prevalence, risk factors, and subtypes of...*29th October, 2009
Department of Ophthalmology, University of Munich, Munich, Germany.- Acta Ophthalmol. 2009 Oct 27. ([DOI Direct Link](#))

BioNews Results for Choroidal Neovascularization

- [Intravitreal Bevacizumab for Choroidal Neovascularization Secondary To Presumed Ocular Histoplasmosis Syndrome](#)
MDLinx: Nov 19 2009 11:00AM Matching: choroidal neovascularization
- [Choroidal Vasculopathy: Research on choroidal vasculopathy reported by scientists at RIKEN](#)
NewsRX: Nov 6 2009 6:26AM Matching: choroidal neovascularization
- [Ranibizumab Can Help Patients With Age-Related Macular Degeneration and Diabetic Macular Oedema Regain Vision:](#)
Doctors Guide: Oct 29 2009 12:29AM Matching: choroidal neovascularization
- [Choroidal Filling Delay in Choroidal Neovascularization due to Pathologic Myopia](#)
British Journal of Ophthalmology: Oct 21 2009 10:44AM Matching: choroidal neovascularization
- [Two-Year Visual Results for Older Asian Women Treated with Photodynamic Therapy or Bevacizumab for Myopic Choroidal Neovascularization](#)
MDLinx: Oct 21 2009 1:02PM Matching: choroidal neovascularization



Choroidal Neovascularization Patents:

- 7541186- [Method of generating human retinal progenitors from embryonic stem cells](#)
- 7564946- [Orthovoltage radiotherapy](#)
- 7566721- [Substituted thienol\[2,3-d\]pyrimidines as kinase inhibitors](#)
- 7566765- [Heterocyclic compounds containing a nine-membered carbon-nitrogen ring](#)
- 7566770- [Humanized collagen antibodies and related methods](#)
- 7567349- [Speckle reduction in optical coherence tomography by path length encoded angular compounding](#)
- 7569584- [4-\(2-methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl\)-1,3-dihydro-imidazole-- 2-thione as specific alpha.sub.2b agonist and methods of using the same](#)
- 7572442- [Selected antibody compositions for binding to aminophospholipids](#)
- 7572448- [Combined cancer treatment methods using selected antibodies to aminophospholipids](#)
- 7572821- [Compounds for the treatment of proliferative disorders](#)
- 7575879- [Polypeptides homologous to VEGF and BMP1](#)
- 7563255- [Implantable drug delivery device and use thereof](#)
- 7563222- [Methods and apparatus for intraocular brachytherapy](#)
- 7560552- [Thiopyrimidine and isothiazolopyrimidine kinase inhibitors](#)
- 7541333- [Angiogenically effective unit dose of FGF-2 and method of use](#)
- 7541337- [Methods and compositions for the treatment of peripheral artery disease](#)
- 7544677- [Inhibitors of Akt activity](#)
- 7544703- [Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein](#)
- 7550154- [Methods of treatment with drug loaded polymeric materials](#)
- 7550478- [Tyrosine kinase inhibitors](#)
- 7551293- [Method and apparatus for three-dimensional spectrally encoded imaging](#)
- 7553496- [VEGF-A as an inhibitor of angiogenesis and methods of using same](#)
- 7553845- [Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives](#)
- 7556378- [Intraoperative estimation of intraocular lens power](#)
- 7576089- [3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors](#)
- 7576209- [Inhibitors of Akt activity](#)
- 7601341- [Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis](#)
- 7601694- [CLK-peptide and SLK-peptide](#)
- 7601840- [Carboline derivatives useful in the inhibition of angiogenesis](#)
- 7604628- [Multi-cap reservoir devices for controlled release or exposure of reservoir contents](#)
- 7605235- [Anti-tissue factor antibodies and compositions](#)
- 7608635- [Pyrazole compounds that modulate HSP90 activity](#)
- 7611704- [Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids](#)
- 7612082- [Prostaglandin EP.sub.4 antagonists](#)
- 7615223- [Selected immunoconjugates for binding to aminophospholipids](#)
- 7618970- [3-aminocyclopentanecarboxamides as modulators of chemokine receptors](#)
- 7598283- [Indazole, benzisoxazole, and benzisothiazole kinase inhibitors](#)
- 7597886- [Tumor necrosis factor-gamma](#)
- 7595430- [Methods and animal model for analyzing age-related macular degeneration](#)

- 7579355- [Inhibitors of Akt activity](#)
- 7582080- [Implantable, tissue conforming drug delivery device](#)
- 7585517- [Transscleral delivery](#)
- 7585895- [Therapeutic substituted cyclopentanes](#)
- 7589057- [Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems](#)
- 7589068- [Inhibitors of Akt activity](#)
- 7592016- [Methods for preparing and using implantable substance delivery devices](#)
- 7592330- [Methods and compositions for preserving the viability of photoreceptor cells](#)
- 7593559- [Method and system of coregistrating optical coherence tomography \(OCT\) with other clinical tests](#)
- 7595047- [Compositions and methods for promoting or inhibiting angiogenesis](#)
- 7620147- [Orthovoltage radiotherapy](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

